Regenerex Pharma, a company specializing in advanced wound closure systems for chronic wounds, today announced the development of new product formulations designed to accelerate deep tissue regeneration through enhanced scaffolding facilitation and cell proliferation. Building on its patented QBx technology, Regenerex will now incorporate ovine nano-collagen into its wound healing protocols. This highly refined biomaterial, due to its ultra-small molecular size, provides an ideal scaffolding matrix to support and accelerate cellular growth, making it especially beneficial in cases requiring deeper tissue regeneration.
As part of this strategic advancement, Regenerex has entered into a licensing agreement with Holista Colltech, a globally recognized producer of high-purity ovine collagen. Holista’s collagen is derived from ethically sourced, disease-free Australian sheep, produced under Australia’s rigorous animal health standards.
“Ovine collagen represents a significant step forward in wound care innovation,” said Greg Pilant, CEO of Regenerex Pharma, Inc. “Unlike traditional mammalian sources such as bovine or porcine collagen, ovine nano-collagen is not only safer—avoiding concerns like mad cow disease—but also more culturally and religiously acceptable in many global markets.”
This collaboration allows Regenerex to bring cutting-edge, biologically advanced wound care solutions to both U.S. and international markets. The integration of ovine nano-collagen with Regenerex’s QBx technology reflects the company’s commitment to providing safe, effective, and inclusive wound healing options.
